Name | beta-Epoetin |
---|
Description | Epoetin beta (rhEPO) is a recombinant form of erythropoietin. Epoetin beta is responsible for the maintenance of erythropoiesis and can be used for anaemia research[1]. |
---|---|
Related Catalog | |
In Vivo | Epoetin beta (rhEPO) (1000 IU/kg; s.c.; three times per week over 14 days) prevents anaemia and enhances the radiosensitivity of solid growing DS-sarcomas[2]. Animal Model: Male Sprague-Dawley rats, body weight 140-170 g[2] Dosage: 1000 IU/kg Administration: Subcutaneous injection, three times per week over 14 days starting 9 days before tumour implantation. Solid DS-sarcomas were induced by injecting DS-sarcoma cells (0.4 mL, approximately 104 cells/uL) subcutaneously into the hind food dorsum. A prolonged anaemia was induced in all animals by a single i.v. dose of carboplatin (45 mg/kg dissolved in isotonic saline at a concentration of 20 mg/mL) into the tail vein 3 days before tumour implantation. Result: Prevented anaemia and significantly increased the radiosensitivity of solid growing DS-sarcomas, tumours showing pronounced hypoxia even under non-anaemic control conditions. |
References |
No Any Chemical & Physical Properties |